Lantheus Holdings (LNTH) Receives Daily News Sentiment Score of 0.15
Headlines about Lantheus Holdings (NASDAQ:LNTH) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lantheus Holdings earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 45.3595457291179 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
- ETFs with exposure to Lantheus Holdings, Inc. : November 20, 2017 (finance.yahoo.com)
- Timothy G. Healey Sells 11,314 Shares of Lantheus Holdings, Inc. (LNTH) Stock (americanbankingnews.com)
- Lantheus Medical Imaging, Inc — Moody’s: Lantheus’ term loan repricing proposal is credit positive (finance.yahoo.com)
- Insider Selling: Lantheus Holdings, Inc. (LNTH) Insider Sells 11,917 Shares of Stock (americanbankingnews.com)
Shares of Lantheus Holdings (LNTH) opened at $22.80 on Thursday. Lantheus Holdings has a fifty-two week low of $7.95 and a fifty-two week high of $24.10. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. The stock has a market cap of $877.64, a P/E ratio of 20.89, a P/E/G ratio of 1.86 and a beta of 0.92.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.04. Lantheus Holdings had a net margin of 9.59% and a negative return on equity of 46.45%. The business had revenue of $79.94 million for the quarter, compared to the consensus estimate of $77.18 million. During the same period last year, the firm earned $0.15 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. analysts expect that Lantheus Holdings will post 1.05 EPS for the current fiscal year.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $26.00 target price on the stock in a report on Tuesday, November 7th. Credit Suisse Group raised their target price on shares of Lantheus Holdings from $19.00 to $23.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Jefferies Group LLC raised their target price on shares of Lantheus Holdings from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Wells Fargo & Company upgraded shares of Lantheus Holdings from a “market perform” rating to an “outperform” rating in a report on Thursday, November 2nd. Finally, BidaskClub cut shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Lantheus Holdings currently has an average rating of “Buy” and an average price target of $24.50.
In other Lantheus Holdings news, CFO John W. Crowley sold 6,755 shares of the stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $18.41, for a total value of $124,359.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy G. Healey sold 11,314 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $21.51, for a total transaction of $243,364.14. The disclosure for this sale can be found here. Insiders sold 644,638 shares of company stock worth $11,079,593 over the last quarter. Insiders own 2.30% of the company’s stock.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.